Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gopichand Gottipati
Observed name:
Gottipati, Gopichand
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
Uppsala University,
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Virginia Commonwealth University
ORCID:
0009-0009-5654-5345
Observed ORCID:
0009-0009-5654-5345
OpenAlex ID:
A5040919731
Modeling a Composite Score in Parkinson’s Disease Using Item Response Theory
2017
·
Gopichand Gottipati
, Mats O. Karlsson
, et al.
·
The AAPS Journal
·
43
PDF
Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson’s Disease Rating Scales
2019
·
Gopichand Gottipati
, Alienor C. Berges
, et al.
·
Pharmaceutical Research
·
17
PDF
Meta-Analysis of the Placebo Response in Chronic and Episodic Migraine: Insights from Migraine Preventive Drug Trials
2025
·
Anantha Ram Nookala
, Nimishraj Panse
, et al.
·
The AAPS Journal
·
3
Pediatric Extrapolation in Neuropsychiatric Drug Development: Leveraging Pharmacokinetic and Pharmacodynamic Strategies to Facilitate FDA Approvals
2026
·
Anantha Ram Nookala
, William A. Murphy
, et al.
·
Clinical Pharmacology & Therapeutics
·
1
An Innovative Pharmacometric Approach for the Simultaneous Analysis of Frequency, Duration and Severity of Migraine Events
2020
·
Alejandro Perez-Pitarch
, Gopichand Gottipati
, et al.
·
Pharmaceutical Research
·
1
Differentiation between Parkinson's disease patients and SWEDDs based on the MDS-UPDRS
2017
·
Sven C. van Dijkman
, Gopichand Gottipati
, et al.
·
European Journal of Neurology
·
1
Prediction of Human Systemic, Biologically Relevant Pharmacokinetic (pk) Properties Using Quantitative Structure Pharmacokinetic Relationships (qspkr) and Interspecies Pharmacokinetic Allometric Scaling (pk-as) Approaches for Four Different Pharmacological Classes of Compounds
2014
·
Gottipati, Gopichand
·
VCU Scholars Compass (Virginia Commonwealth University)
·
1
FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease
2026
·
Poonam R. Delvadia
, Anantha Ram Nookala
, et al.
·
The Journal of Clinical Pharmacology
PDF
Application of Model‐Informed Approaches in Neuroscience Drug Development and Regulatory Decision‐Making
2026
·
Michael Bewernitz
, Anantha Ram Nookala
, et al.
·
The Journal of Clinical Pharmacology
A Survey of Model Informed Approaches in Neuroscience Drug Development
2024
·
Michael Bewernitz
, Vishnu Sharma
, et al.
PDF
Show more works
View as search
Works count:
10
Citation count:
67
H-index:
3
I10-index:
2
Year
Topic
Type